Jock,
After Epichem lost its longstanding key contract. the BoD would have decided that after 20 years (under difrferent managements, including Epichem's own) enough was enough. Clearly it wasn't an easy decision since that key DNDI contract was lost in March. The monepantel project was to have priority and they obviously saw Epichem's troubles as a danger to that. Why else would they have taken this drastic action? You don't need to be on the inside to figure that out.
Ann: MND Biomarkers and Pharmacodynamics Results, page-331
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.5¢ | 19.5¢ | $459.0K | 2.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 103700 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 127225 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |